OCULAR THERAPEUTIX, INC Convertible Debt, Noncurrent
OCULAR THERAPEUTIX, INC (OCUL) had Convertible Debt, Noncurrent of $9.14 million as of 2023-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt, Excluding Current Maturities
us-gaap:ConvertibleDebtNoncurrent · last filed 2025-03-03
- 2023-12-31: Convertible Debt, Noncurrent $9.14M.
- 2023-09-30: Convertible Debt, Noncurrent $8.77M.
- 2023-06-30: Convertible Debt, Noncurrent $29.98M.
- 2023-03-31: Convertible Debt, Noncurrent $29.36M.
| Period end | Convertible Debt, Noncurrent |
|---|---|
| 2023-12-31 | $9.14M 10-K · filed 2025-03-03 |
| 2023-09-30 | $8.77M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $29.98M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $29.36M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $28.75M 10-K · filed 2024-03-11 |
| 2022-09-30 | $28.15M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $27.57M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $27.00M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $26.43M 10-K · filed 2023-03-06 |
| 2021-09-30 | $25.89M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $25.35M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $24.82M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $24.31M 10-K · filed 2022-02-28 |
| 2020-09-30 | $23.80M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $26.35M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $25.30M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $24.30M 10-K · filed 2021-03-11 |
| 2019-09-30 | $23.15M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $23.90M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $23.01M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |